antibiotic | mecfa

MECFA Blog

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

ContraFect will receive funding from the Cystic Fibrosis Foundation to conduct preclinical research about the potential of direct lytic...

Coronavirus Update: New COVID-19 Antibiotic, WLBU2, Has Been Developed That Could Fight Lung Infecti

According to a report from The Dailymail, a new COVID-19 antibiotic has been developed that could potentially fight lung infections, such...

Staphylococcus Aureus in CF Airways Change With Age, Antibiotic Use, Study Says

Different types of Staphylococcus aureus can be found persistently in the airways of cystic fibrosis (CF) patients, but this bacteria...

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Stenotrophomonas maltophilia is one of the most common emerging multi-drug resistant organisms found in the lungs of people with cystic...

IGF2R Blood Levels May Help Predict Antibiotic Response in CF Pulmonary Exacerbations, Study Says

Measuring the levels of insulin-like growth factor 2 receptor (IGF2R) during the first days of treatment with intravenous antibiotics...

IGF2R Blood Levels May Help Predict Antibiotic Response in CF Pulmonary Exacerbations, Study Says

Measuring the levels of insulin-like growth factor 2 receptor (IGF2R) during the first days of treatment with intravenous antibiotics...

Powerful weapon discovered to fight antibiotic resistance in Staphylococcus aureus

Staphylococcus aureus bacteria are a major cause of serious infections that often persist despite antibiotic treatment, but scientists at...

Murepavadin Antibiotic Well-tolerated by Animals Infected with Pseudomonas Aeruginosa, Preclinical D

Murepavadin (POL7080), Polyphor‘s lead investigational antibiotic targeting Gram-negative bacteria, behaved as expected and was...

Slammed by Side Effects: The Downside of Antibiotics

Everyone with cystic fibrosis knows that feeling. Sometimes, it creeps up on you slowly. Other times, it hits right away, like a truck...

Paying more attention to antibiotic dosing could improve clinical outcomes for CF patients

Download PDF Copy Children and young adults with cystic fibrosis (CF) whose lung infections were treated with suboptimal doses of...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p